Pfizer Inc. (PFE) Rating Reiterated by Sanford C. Bernstein

Gladys Abbott
May 9, 2017

Its quick ratio for most recent quarter is 1.00 along with current ratio for most recent quarter of 1.30. Over the same time span, the stock marked US$43.89 as its best level and the lowest price reached was US$36.1.

Other large investors have also recently modified their holdings of the company. Excalibur Management Corp increased its stake in Pfizer by 1.3% in the first quarter. Gierl Augustine Investment Management Inc now owns 3,718 shares of the biopharmaceutical company's stock worth $126,000 after buying an additional 205 shares during the period. Finally, Dubuque Bank & Trust Co. boosted its position in Pfizer by 2.1% in the first quarter. Douglass Winthrop Advsrs Ltd Liability Com invested in 61,744 shares or 0.14% of the stock. Finally, Nelson Roberts Investment Advisors LLC raised its stake in shares of Pfizer by 53.1% in the third quarter. 0 have given the stock a Hold rating, 0 as Underperform and 0 as Sell. The company's institutional ownership is monitored at 57 percent. It has a dividend yield of 3.80% and a 5 year dividend growth rate of 8.27%. BMO Capital Markets reissued a "hold" rating and set a $33.00 price target on shares of Pfizer in a research report on Thursday, April 27th.

According to Finviz reported data, The SMA20 of the stock is at -1.21 percent, SMA50 is -1.88 percent, while SMA200 is 1.1 percent.

The stock added in the prior trading session by 0.09%, closing at the stock price of $33.48. The New York-based Clark Estates Inc Ny has invested 9.15% in the stock. This is an increase of 360% compared to the average volume of 7,125 call options. (NYSE:PFE) to report earnings on August, 1. First Manhattan Co. now owns 6,946 shares of the technology company's stock worth $331,000 after buying an additional 36 shares in the last quarter. The company earned $12.78 billion during the quarter, compared to analyst estimates of $13.09 billion.

The company's net profit margin stands at 5.20% whereas its return on equity (ROE) is -59.40%. Typically, they estimate what the company's earnings and cash flow will be for the next couple of years, and then apply a ratio - such as a price-to-earnings ratio - to those estimates to determine what the future stock price should theoretically be. During the same period in the previous year, the business earned $0.67 earnings per share.

More news: Malaysia, North Korea Asian Cup qualifier to go ahead in Pyongyang

Many analysts are providing their Estimated Earnings analysis for Pfizer Inc. and for the current quarter 15 analysts have projected that the stock could give an Average Earnings estimate of $0.66/share.

Total debt to equity ratio of the company for most recent quarter is 0.71 whereas long term debt to equity ratio for most recent quarter is 0.53. Investors of record on Friday, May 12th will be given a dividend of 0.32 per share by the biopharmaceutical company on Thursday, June 1st. The ex-dividend date of this dividend is Wednesday, May 10th. Pfizer's dividend payout ratio (DPR) is 110.35%. Perhaps, that suggests something about why 0.23% of the outstanding share supply is held by institutional investors. If you are accessing this story on another domain, it was illegally copied and republished in violation of U.S. & global copyright & trademark legislation.

Pfizer (NYSE:PFE) opened at 33.48 on Monday.

Several research analysts have recently weighed in on the stock. Atlantic Securities raised shares of AMETEK from a "neutral" rating to an "overweight" rating and boosted their target price for the company from $48.00 to $62.00 in a research note on Wednesday, February 15th. (NYSE:PFE) on Tuesday, November 3 with "Buy" rating. Jefferies has "Buy" rating and $40 target. The reason? Pfizer and NICE have scheduled a pause in their proceedings, giving Pfizer time to submit an updated evidence package for the cost-effectiveness gatekeeper's consideration-and the company doesn't want to stall access in the meantime. Eleven analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of "Buy" and an average target price of $37.83. Its Average True Range (ATR) value figured out at 1.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Mikael Dolsten sold 30,970 shares of Pfizer stock in a transaction that occurred on Thursday, March 2nd. The recommendation scale measures the value from 1 to 5, where 1 means "Strong Buy" and 5 stands for "Sell". Following the completion of the transaction, the insider now owns 64,719 shares of the company's stock, valued at $2,233,452.69.

Other reports by LeisureTravelAid

Discuss This Article